Sato M, Harada K, Yura Y, Azuma M, Kawamata H, Iga H, Tsujimoto H, Yoshida H, Adachi M
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Japan.
Apoptosis. 1997;2(3):313-8. doi: 10.1023/a:1026493205097.
A patient with histopathological recurrent oral cancer with well-differentiated squamous cell carcinoma, was treated with differentiation- and apoptosis-inducing agent, vesnarinone, per os at a dose of 180 mg/day for 56 days and then at a dose of 60 mg/day for 93 days. The vesnarinone administration caused complete remission of the tumour. It has been found by immunohistochemical staining and PCR-SSCP analysis that the recurrent tumour has wild type p53 gene and relative high level of LeY expression as well as DNA fragmentation in the cancer cells, as assessed by nick-end labelling. These findings suggest that the cure of oral squamous cell carcinoma observed in this case might be associated with induction of differentiation and apoptosis of cancer cells by vesnarinone.
一名患有组织病理学复发性口腔癌且为高分化鳞状细胞癌的患者，口服诱导分化和凋亡的药物维司力农，剂量为每日180毫克，持续56天，之后剂量为每日60毫克，持续93天。维司力农给药后肿瘤完全缓解。通过免疫组织化学染色和PCR-SSCP分析发现，复发性肿瘤具有野生型p53基因、相对较高水平的LeY表达以及通过缺口末端标记评估的癌细胞中的DNA片段化。这些发现表明，该病例中观察到的口腔鳞状细胞癌的治愈可能与维司力农诱导癌细胞分化和凋亡有关。
